Literature DB >> 28716556

Impact of pneumococcal conjugate vaccine (PCV7 and PCV13) on pneumococcal invasive diseases in Italian children and insight into evolution of pneumococcal population structure.

Romina Camilli1, Fabio D'Ambrosio2, Maria Del Grosso2, Fernanda Pimentel de Araujo2, Maria Grazia Caporali2, Martina Del Manso2, Giovanni Gherardi3, Fortunato D'Ancona2, Annalisa Pantosti2.   

Abstract

BACKGROUND: The use of PCV7 for children immunization was gradually implemented in the Italian regions starting from 2006 and was replaced by PCV13 in 2010-2011. In this study we aimed to assess the PCV impact on invasive pneumococcal diseases (IPD) incidence, serotype distribution and antibiotic resistance in Italian children under 5years old.
METHODS: All IPD cases in children from 5 Italian regions (Emilia-Romagna, Lombardia, A. P. Bolzano, A. P. Trento, and Piemonte) reported through the nationwide surveillance system during 2008-2014 were included in this study. Pneumococcal isolates were subjected to serotyping, antibiotic susceptibility testing, and clonal analysis according to standard methods.
RESULTS: During the study period overall IPD incidence decreased from 7.8 cases/100,000 inhabitants in 2008 to 3.0 cases/100,000 in 2014 (61% decrease, P<0.001). In particular, from 2008 to 2014, PCV7-type IPD decreased from 2.92 to 0.13 cases/100,000 inhabitants (95% decrease, P<0.001) while PCV13-non-PCV7 type IPD decreased from 3.2 to 0.89 cases/100,000 inhabitants (72% decrease, P=0.008). Conversely, non-vaccine serotype (NVS) IPD increased overtime, becoming more common than PCV13 serotype IPD in 2013-2014. Emergent NVS 24F and 12F were the most prevalent in 2014. Antibiotic resistance testing revealed an overall increasing trend in penicillin resistance, from 14% in 2008 to 23% in 2014. Erythromycin resistance showed a downward trend, from 38% in 2008 to 27% in 2014. While in 2008 PCV13 serotypes were the major responsible for antibiotic resistance, during the following years antimicrobial resistance due to NVS increased, mainly as a result of expansion of pre-existing clones.
CONCLUSIONS: Both PCVs led to a substantial decrease in vaccine-related IPD incidence in the children population. However NVS-related IPD increased, becoming the most prevalent in the last two-years period. Continuous surveillance is an essential tool to monitor evolution of pneumococcal population causing IPD in children.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antibiotic resistance; Children; IPD; PCV13; PCV7; Pneumococcal clones; Streptococcus pneumoniae

Mesh:

Substances:

Year:  2017        PMID: 28716556     DOI: 10.1016/j.vaccine.2017.07.010

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  17 in total

1.  Penicillin-Binding Protein Typing, Antibiotic Resistance Gene Identification, and Molecular Phylogenetic Analysis of Meropenem-Resistant Streptococcus pneumoniae Serotype 19A-CC3111 Strains in Japan.

Authors:  Satoshi Nakano; Takao Fujisawa; Yutaka Ito; Bin Chang; Yasufumi Matsumura; Masaki Yamamoto; Shigeru Suga; Makoto Ohnishi; Miki Nagao
Journal:  Antimicrob Agents Chemother       Date:  2019-08-23       Impact factor: 5.191

2.  Whole-Genome Sequencing Analysis of Multidrug-Resistant Serotype 15A Streptococcus pneumoniae in Japan and the Emergence of a Highly Resistant Serotype 15A-ST9084 Clone.

Authors:  Satoshi Nakano; Takao Fujisawa; Yutaka Ito; Bin Chang; Yasufumi Matsumura; Masaki Yamamoto; Shigeru Suga; Makoto Ohnishi; Miki Nagao
Journal:  Antimicrob Agents Chemother       Date:  2019-04-25       Impact factor: 5.191

Review 3.  Prevention of Invasive Pneumococcal Disease: Problems Emerged After Some Years of the 13-Valent Pneumococcal Conjugate Vaccine Use.

Authors:  Nicola Principi; Giuseppe Di Cara; Ilaria Bizzarri; Chiara Isidori; Paola Borgia; Costanza Mignini; Marco Saponara; Alberto Argentiero; Susanna Esposito
Journal:  Curr Infect Dis Rep       Date:  2018-01-24       Impact factor: 3.725

4.  Streptococcus pneumoniae vaccination strategies and its expected impact on penicillin non-susceptibility in children under the age of five: Let's recap!

Authors:  Hiba Sabbar; Chafik Mahraoui; Magdalena Bastìas Garcià; Imane Jroundi
Journal:  Vaccine X       Date:  2022-05-14

5.  Characteristics of Serotype 3 Invasive Pneumococcal Disease before and after Universal Childhood Immunization with PCV13 in Massachusetts.

Authors:  Rotem Lapidot; Kimberly M Shea; Inci Yildirim; Howard J Cabral; Stephen I Pelton; The Massachusetts Department Of Public Health
Journal:  Pathogens       Date:  2020-05-21

6.  Dominance of vaccine serotypes in pediatric invasive pneumococcal infections in Portugal (2012-2015).

Authors:  Catarina Silva-Costa; Maria J Brito; Sandra I Aguiar; Joana P Lopes; Mário Ramirez; José Melo-Cristino
Journal:  Sci Rep       Date:  2019-01-09       Impact factor: 4.379

7.  Molecular characterization and epidemiology of Streptococcus pneumoniae serotype 24F in Denmark.

Authors:  Ioanna Drakaki Kavalari; Kurt Fuursted; Karen A Krogfelt; H-C Slotved
Journal:  Sci Rep       Date:  2019-04-02       Impact factor: 4.379

8.  Regional variations in serotype distribution and vaccination status in children under six years of age with invasive pneumococcal disease in Germany.

Authors:  Stephanie Perniciaro; Matthias Imöhl; Christina Fitzner; Mark van der Linden
Journal:  PLoS One       Date:  2019-01-09       Impact factor: 3.240

9.  Estimating the Clinical and Economic Impact of Switching from the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) to the 10-Valent Pneumococcal Conjugate Vaccine (PCV10) in Italy.

Authors:  Filippo Ansaldi; Sarah Pugh; Daniela Amicizia; Roberto Di Virgilio; Cecilia Trucchi; Andrea Orsi; Alessandro Zollo; Giancarlo Icardi
Journal:  Pathogens       Date:  2020-01-22

10.  Molecular serotype-specific identification of Streptococcus pneumoniae using loop-mediated isothermal amplification.

Authors:  Chika Takano; Yoko Kuramochi; Mitsuko Seki; Dong Wook Kim; Daisuke Omagari; Mari Sasano; Bin Chang; Makoto Ohnishi; Eun Jin Kim; Kazumasa Fuwa; Paul E Kilgore; Tomonori Hoshino; Satoshi Hayakawa
Journal:  Sci Rep       Date:  2019-12-27       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.